Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-05-06 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 84.8 KB | ||
| 2024-05-06 22:30 |
Monthly information on share capital and company voting rights
|
English | 75.6 KB | ||
| 2024-05-06 08:00 |
Cellectis annonce la réalisation de l’investissement additionnel d’AstraZeneca
|
French | 99.3 KB | ||
| 2024-05-06 08:00 |
Cellectis Announces Completion of the Additional Equity Investment by AstraZene…
|
English | 81.6 KB | ||
| 2024-05-02 22:30 |
Cellectis nomme Arthur Stril directeur financier par intérim
|
French | 58.8 KB | ||
| 2024-05-02 22:30 |
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
|
English | 53.2 KB | ||
| 2024-04-29 22:46 |
Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’e…
|
French | 354.3 KB | ||
| 2024-04-29 22:46 |
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
|
English | 421.4 KB | ||
| 2024-04-22 22:30 |
Cellectis présente de nouveaux procédés d’éditions par TALEN® permettant une in…
|
French | 100.8 KB | ||
| 2024-04-22 22:30 |
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gen…
|
English | 81.5 KB | ||
| 2024-04-10 22:30 |
Cellectis publie une nouvelle approche d'édition intronique pour le traitement …
|
French | 118.5 KB | ||
| 2024-04-10 22:30 |
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of…
|
English | 107.5 KB | ||
| 2024-04-08 22:30 |
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process fo…
|
English | 71.2 KB | ||
| 2024-04-08 22:30 |
Cellectis présentera deux posters sur un nouveau procédé d’édition par TALEN® p…
|
French | 84.0 KB | ||
| 2024-04-05 01:33 |
CORRECTION : Information mensuelle relative au nombre total des droits de vote …
|
French | 120.1 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
